person · Reporting owner
Anzalone Christopher Richard
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director · Chief Executive Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,792,739 |
Last balance in matching sequence
After 2026-01-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-01-02 · Sale · Disposed 7,416 · Balance 3,798,510 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Partial disposition of shares to satisfy tax withholding obligations. F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.28 to $66.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 2 · 2026-01-02 · Sale · Disposed 5,771 · Balance 3,792,739 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: Partial disposition of shares to satisfy tax withholding obligations. F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.21 to $66.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: Partial disposition of shares to satisfy tax withholding obligations.
F3: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $65.28 to $66.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.21 to $66.58, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 20, 2019 Filed Sep 25, 2019 01:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 4,250 | $5.10 | $21,675.00 |
DisclosureSEC source: 0001209191-19-050606 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,146,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was completed as the underlying option was due to expire in October 2019. Read SEC document |
| May 24, 2019 Filed May 29, 2019 22:57 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 9,376 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001209191-19-033290 · doc4.xml · derivative · entry 4 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,133,418 Underlying: Common Stock · 9,376 shares Expires 2022-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| May 24, 2019 Filed May 29, 2019 22:57 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionStock Option (right to buy) · Derivative | 40,072 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001209191-19-033290 · doc4.xml · derivative · entry 3 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,142,794 Underlying: Common Stock · 40,072 shares Expires 2023-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents first vesting date. Option vested over four years from date of grant. Read SEC document |
| May 24, 2019 Filed May 29, 2019 22:57 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 9,376 | $2.62 | $24,565.12 |
DisclosureSEC source: 0001209191-19-033290 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,141,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| May 24, 2019 Filed May 29, 2019 22:57 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Exercise / conversionCommon Stock | 40,072 | $2.01 | $80,544.72 |
DisclosureSEC source: 0001209191-19-033290 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,132,527 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2019 Filed Apr 5, 2019 22:57 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 50,000 | $19.30 | $965,000.00 |
DisclosureSEC source: 0001209191-19-023887 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092,455 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.30 to $19.31, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:49 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001467 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,142,455 F1 · shares: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of three predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that must be achieved within two years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole. F2 · balance_after: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 22:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 90,000 | $13.92 | $1,252,800.00 |
DisclosureSEC source: 0001209191-18-063963 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,542,455 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.92 to $13.99, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 333,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| December 12, 2018 Filed Dec 14, 2018 22:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon STock | 90,000 | $14.07 | $1,266,300.00 |
DisclosureSEC source: 0001209191-18-062779 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,632,455 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.58 to $14.39, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 513,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| November 09, 2018 Filed Nov 10, 2018 00:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,300 | $14.95 | $79,235.00 |
DisclosureSEC source: 0001209191-18-058026 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,722,455 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.92 to $15.00, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes a total of 693,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| November 09, 2018 Filed Nov 10, 2018 00:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 76,200 | $14.35 | $1,093,470.00 |
DisclosureSEC source: 0001209191-18-058026 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,727,755 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.87 to $14.85, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 20:23 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 64,834 | $14.45 | $936,851.30 |
DisclosureSEC source: 0001209191-18-049552 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,803,955 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $14.65, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F4 · balance_after: Includes a total of 856,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| August 31, 2018 Filed Sep 5, 2018 20:23 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 100,000 | $14.45 | $1,445,000.00 |
DisclosureSEC source: 0001209191-18-049552 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,868,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.40 to $14.54, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 16, 2018 Filed Mar 16, 2018 22:09 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 26,000 | $7.40 | $192,400.00 |
DisclosureSEC source: 0001209191-18-020349 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,968,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported on Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.40 to $7.41, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 1,186,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| March 15, 2018 Filed Mar 15, 2018 22:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 100,000 | $7.41 | $741,000.00 |
DisclosureSEC source: 0001209191-18-019971 · doc4.xml · nonDerivative · entry 3 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,994,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The prices reported on Column 4 are a weighted average prices. The shares sold on 3/13/18 were sold in multiple transactions at prices ranging from $7.29 to $7.56, inclusive. The shares sold on 3/14/18 were sold in multiple transactions at prices ranging from $7.26 to $7.69, inclusive. The shares sold on 3/15/18 were sold in multiple transactions at prices ranging from $7.40 to $7.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes a total of 1,186,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 22:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 100,000 | $7.44 | $744,000.00 |
DisclosureSEC source: 0001209191-18-019971 · doc4.xml · nonDerivative · entry 2 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The prices reported on Column 4 are a weighted average prices. The shares sold on 3/13/18 were sold in multiple transactions at prices ranging from $7.29 to $7.56, inclusive. The shares sold on 3/14/18 were sold in multiple transactions at prices ranging from $7.26 to $7.69, inclusive. The shares sold on 3/15/18 were sold in multiple transactions at prices ranging from $7.40 to $7.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 22:58 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 100,000 | $7.43 | $743,000.00 |
DisclosureSEC source: 0001209191-18-019971 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,194,789 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The prices reported on Column 4 are a weighted average prices. The shares sold on 3/13/18 were sold in multiple transactions at prices ranging from $7.29 to $7.56, inclusive. The shares sold on 3/14/18 were sold in multiple transactions at prices ranging from $7.26 to $7.69, inclusive. The shares sold on 3/15/18 were sold in multiple transactions at prices ranging from $7.40 to $7.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:22 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001456 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,294,789 F1 · shares: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of four predetermined performance goals related to the advancement of the Company's clinical and preclinical programs and business development that must be achieved within three years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole. F2 · balance_after: Includes a total of 1,838,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| April 12, 2017 Filed Apr 14, 2017 20:07 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 978,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026974 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,789 F1 · shares: Represents the maximum number of shares underlying a restricted stock unit that may be earned based on the achievement of six predetermined performance goals related to the advancement of the Company's preclinical programs and business development that must be achieved within two years. If the performance goals are not met within the required time periods, the award will be forfeited in part or in whole. F2 · balance_after: Includes a total of 1,338,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole. Read SEC document |
| December 13, 2016 Filed Dec 16, 2016 02:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | Tax withholdingCommon Stock | 300,444 | $1.27 | $381,563.88 |
DisclosureSEC source: 0001209191-16-155526 · doc4.xml · nonDerivative · entry 1 Anzalone Christopher Richard · CIK 0001423029 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,789 F1 · kind: This disposition reflects the payment of tax liability by withholding shares incident to the vesting of restricted stock units previously granted. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.